24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with
mild Alzheimer's disease.
60% of participants will receive AADvac1 and 40% of participants will receive placebo.